CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment

NDA FilingAXPAXLIPositive
AI Analysis

Summary

Ocular Therapeutix has completed FDA alignment discussions for AXPAXLI and plans to submit an NDA in Q4 2026.

Importance:6/10
Sentiment:
0.50
NDAFDAregulatoryAXPAXLI
Related Companies

Read the original article

Published by yahoo_finance on July 23, 2026 12:02 AM

Read Original